NovoCure (NVCR) Net Cash Flow Growth (3y) (2017 - 2026)
NovoCure (NVCR) Net Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -9.45% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 60.16% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -85.83% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 43.26% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -26.30% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 21.48% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -127.77% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 269.22% |
| 10 | NovoCure | 2.06 Bn | 1.62 Bn | 142.48 Mn | 30.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.38% |
| Mar 31, 2026 | -27.73% |
| Dec 31, 2025 | -23.40% |
| Sep 30, 2025 | 52.66% |
| Jun 30, 2025 | -49.70% |
| Mar 31, 2025 | -27.13% |
| Dec 31, 2024 | 63.72% |
| Sep 30, 2024 | -60.29% |
| Jun 30, 2024 | -117.89% |
| Mar 31, 2024 | 39.06% |
| Dec 31, 2023 | 100.21% |
| Sep 30, 2023 | -26.48% |
| Jun 30, 2023 | -58.37% |
| Mar 31, 2023 | 176.49% |
| Dec 31, 2022 | -60.22% |
| Sep 30, 2022 | -85.50% |
| Jun 30, 2022 | 84.70% |
| Mar 31, 2022 | -52.39% |
| Dec 31, 2021 | -208.45% |
| Sep 30, 2021 | 238.19% |